Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas

被引:0
作者
Aaminah Khan
Laura D. Gamble
Dannielle H. Upton
Caitlin Ung
Denise M. T. Yu
Anahid Ehteda
Ruby Pandher
Chelsea Mayoh
Steven Hébert
Nada Jabado
Claudia L. Kleinman
Mark R. Burns
Murray D. Norris
Michelle Haber
Maria Tsoli
David S. Ziegler
机构
[1] Children’s Cancer Institute,Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Human Genetics
[2] Lowy Cancer Research Centre,Department of Pediatrics
[3] UNSW Sydney,undefined
[4] McGill University,undefined
[5] McGill University Health Center,undefined
[6] Aminex Therapeutics Inc.,undefined
[7] Centre for Childhood Cancer Research,undefined
[8] UNSW Sydney,undefined
[9] Kids Cancer Centre,undefined
[10] Sydney Children’s Hospital,undefined
[11] High St,undefined
来源
Nature Communications | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Diffuse intrinsic pontine glioma (DIPG) is an incurable malignant childhood brain tumor, with no active systemic therapies and a 5-year survival of less than 1%. Polyamines are small organic polycations that are essential for DNA replication, translation and cell proliferation. Ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme in polyamine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO). Herein we show that polyamine synthesis is upregulated in DIPG, leading to sensitivity to DFMO. DIPG cells compensate for ODC1 inhibition by upregulation of the polyamine transporter SLC3A2. Treatment with the polyamine transporter inhibitor AMXT 1501 reduces uptake of polyamines in DIPG cells, and co-administration of AMXT 1501 and DFMO leads to potent in vitro activity, and significant extension of survival in three aggressive DIPG orthotopic animal models. Collectively, these results demonstrate the potential of dual targeting of polyamine synthesis and uptake as a therapeutic strategy for incurable DIPG.
引用
收藏
相关论文
共 95 条
[1]  
Donaldson SS(2006)Advances toward an understanding of brainstem gliomas J. Clin. Oncol. 24 1266-1272
[2]  
Laningham F(2015)DIPG in children-what can we learn from the past? Front. Oncol. 5 237-97
[3]  
Fisher PG(2017)Genomic insights into diffuse intrinsic pontine glioma Front. Oncol. 7 57-35
[4]  
Vanan MI(2017)Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets Curr. Neuropharmacol. 15 88-263
[5]  
Eisenstat DD(2012)Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology Cancer Treat. Rev. 38 27-4458
[6]  
Lapin DH(2019)International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma J. Neurooncol. 141 253-820
[7]  
Tsoli M(2011)Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma Proc. Natl Acad. Sci. USA 108 4453-559
[8]  
Ziegler DS(2016)The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol. 131 803-579
[9]  
Johung TB(2015)Functionally defined therapeutic targets in diffuse intrinsic pontine glioma Nat. Med. 21 555-14
[10]  
Monje M(2019)The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models Nat. Commun. 10 572-169